Research
Hormonal
New approaches in GLP-1RAs development include multi-agonists and combination therapies.
Practitioners should explore the potential benefits of multi-agonist and combination therapy strategies in GLP-1RA treatments.
StrongSupportsmedium confidence
Researchers have focused their efforts on developing GLP-1 R-based multi-agonists, orally administered GLP-1RAs, and combination therapies utilizing GLP-1RAs.
Why this rating
The information is derived from a comprehensive review of patents.
Source
An updated patent review of GLP-1 receptor agonists (2020-present)
Weiwen Lu et al. · Expert Opinion on Therapeutic Patents · 2023
DOI 10.1080/13543776.2023.2274905
reviewCited 17×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →